Data up to 8-years for Roche’s OCREVUS (ocrelizumab) show early and ongoing treatment significantly reduced risk of requiring a walking aid in relapsing multiple sclerosis and disability progression in primary progressive multiple sclerosis

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice